{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T01:24:17Z","timestamp":1787361857675,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05813-9","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T01:00:25Z","timestamp":1787360425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs)"],"prefix":"10.1007","author":[{"given":"Ilaria","family":"Ammendolia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mondello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioacchino","family":"Calapai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaconcetta","family":"Curr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Midiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Firenzuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Cancellieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Cardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Ardizzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Calapai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"5813_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/ph17020199","volume":"17","author":"WA Aldhaleei","year":"2024","unstructured":"Aldhaleei WA, Abegaz TM, Bhagavathula AS (2024) Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the National Institutes of Health All of Us cohort. Pharmaceuticals (Basel) 17:199. https:\/\/doi.org\/10.3390\/ph17020199","journal-title":"Pharmaceuticals (Basel)"},{"key":"5813_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/aos.17473","volume":"103","author":"A Amini","year":"2025","unstructured":"Amini A, Hamann S, Larsen M (2025) Semaglutide and non-arteritic anterior ischaemic optic neuropathy: review and interpretation of reported association. Acta Ophthalmol 103:615\u2013621. https:\/\/doi.org\/10.1111\/aos.17473","journal-title":"Acta Ophthalmol"},{"key":"5813_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1091978","volume":"14","author":"I Ammendolia","year":"2023","unstructured":"Ammendolia I, Mannucci C, Cardia L, Calapai G, Gangemi S, Esposito E, Calapai F (2023) Pharmacovigilance on cannabidiol as an antiepileptic agent. Front Pharmacol 14:1091978. https:\/\/doi.org\/10.3389\/fphar.2023.1091978","journal-title":"Front Pharmacol"},{"key":"5813_CR4","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131\u20132157. https:\/\/doi.org\/10.1053\/j.gastro.2007.03.054","journal-title":"Gastroenterology"},{"key":"5813_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18:427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5813_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.70037","author":"G Bushi","year":"2025","unstructured":"Bushi G, Khatib MN, Rohilla S, Singh MP, Uniyal N, Ballal S, Bansal P, Bhopte K, Gupta M, Gaidhane AM, Tomar BS, Ashraf A, Ravi Kumar M, Chauhan AS, Sah S, Serhan HA, Shabil M (2025) Association of GLP-1 receptor agonists with risk of suicidal ideation and behaviour: a systematic review and meta-analysis. Diabetes Metab Res Rev. https:\/\/doi.org\/10.1002\/dmrr.70037","journal-title":"Diabetes Metab Res Rev"},{"key":"5813_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/cphy.c190025","volume":"10","author":"EM Davis","year":"2020","unstructured":"Davis EM, Sandoval DA (2020) Glucagon-like peptide-1: actions and influence on pancreatic hormone function. Compr Physiol 10:577\u2013595. https:\/\/doi.org\/10.1002\/cphy.c190025","journal-title":"Compr Physiol"},{"key":"5813_CR8","unstructured":"European Medicines Agency (2024) Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8\u201311 April 2024.\u00a0https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024. Accessed 20 Oct 2025"},{"issue":"1","key":"5813_CR9","doi-asserted-by":"publisher","first-page":"14740","DOI":"10.1038\/s41598-025-98313-4","volume":"15","author":"F Fraenza","year":"2025","unstructured":"Fraenza F, Cagnotta C, Gaio M, Sportiello L, Scavone C, Capuano A, Trama U (2025) Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination. Sci Rep 15:14740. https:\/\/doi.org\/10.1038\/s41598-025-98313-4","journal-title":"Sci Rep"},{"key":"5813_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.euroneuro.2024.02.003","volume":"82","author":"A Guirguis","year":"2024","unstructured":"Guirguis A, Chiappini S, Papanti PGD, Vickers-Smith R, Harris D, Corkery JM, Arillotta D, Floresta G, Martinotti G, Schifano F (2024) Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: insights from pharmacovigilance measures and unmasking analysis. Eur Neuropsychopharmacol 82:82\u201391. https:\/\/doi.org\/10.1016\/j.euroneuro.2024.02.003","journal-title":"Eur Neuropsychopharmacol"},{"key":"5813_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2165\/00002018-200730070-00012","volume":"30","author":"M Hauben","year":"2007","unstructured":"Hauben M (2007) Signal detection in the pharmaceutical industry: integrating clinical and computational approaches. Drug Saf 30:627\u2013630. https:\/\/doi.org\/10.2165\/00002018-200730070-00012","journal-title":"Drug Saf"},{"key":"5813_CR12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.89656","author":"RA Hidalgo Ramos","year":"2025","unstructured":"Hidalgo Ramos RA, Ortiz M, Dufner Krieger S, Secades D (2025) Semaglutide and non-arteritic anterior ischemic optic neuropathy: a systematic review. Cureus. https:\/\/doi.org\/10.7759\/cureus.89656","journal-title":"Cureus"},{"key":"5813_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/14728214.2021.1947240","volume":"26","author":"MM Jepsen","year":"2021","unstructured":"Jepsen MM, Christensen MB (2021) Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs 26:231\u2013243. https:\/\/doi.org\/10.1080\/14728214.2021.1947240","journal-title":"Expert Opin Emerg Drugs"},{"key":"5813_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L (2022) Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne) 13:1043789. https:\/\/doi.org\/10.3389\/fendo.2022.1043789","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5813_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajem.2024.01.010","volume":"78","author":"B Long","year":"2024","unstructured":"Long B, Pelletier J, Koyfman A, Bridwell RE (2024) GLP-1 agonists: a review for emergency clinicians. Am J Emerg Med 78:89\u201394. https:\/\/doi.org\/10.1016\/j.ajem.2024.01.010","journal-title":"Am J Emerg Med"},{"key":"5813_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/14740338.2024.2419989","volume":"24","author":"ZY Luo","year":"2025","unstructured":"Luo ZY, Li X, Chen CT, Kang HH, Zhang ZJ, Wang D, Gong JR (2025) Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology. Expert Opin Drug Saf 24:287\u2013296. https:\/\/doi.org\/10.1080\/14740338.2024.2419989","journal-title":"Expert Opin Drug Saf"},{"key":"5813_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/5584_2020_496","volume":"1307","author":"DB Maselli","year":"2021","unstructured":"Maselli DB, Camilleri M (2021) Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol 1307:171\u2013192. https:\/\/doi.org\/10.1007\/5584_2020_496","journal-title":"Adv Exp Med Biol"},{"key":"5813_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","volume":"23","author":"RS McIntyre","year":"2024","unstructured":"McIntyre RS, Mansur RB, Rosenblat JD, Kwan ATH (2024) The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf 23:47\u201355. https:\/\/doi.org\/10.1080\/14740338.2023.2295397","journal-title":"Expert Opin Drug Saf"},{"key":"5813_CR19","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jad.2024.10.062","volume":"369","author":"RS McIntyre","year":"2025","unstructured":"McIntyre RS, Mansur RB, Rosenblat JD, Rhee TG, Cao B, Teopiz KM, Wong S, Le GH, Ho R, Kwan ATH (2025) Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: a replication study using reports to the World Health Organization pharmacovigilance database (VigiBase\u00ae). J Affect Disord 369:922\u2013927. https:\/\/doi.org\/10.1016\/j.jad.2024.10.062","journal-title":"J Affect Disord"},{"key":"5813_CR20","first-page":"247","volume":"25","author":"MedDRA and pharmacovigilance","year":"2016","unstructured":"MedDRA and pharmacovigilance (2016) a complex and little-evaluated tool. Prescrire Int 25:247\u2013250","journal-title":"Prescrire Int"},{"key":"5813_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, D\u2019Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tsch\u00f6p MH (2019) Glucagon-like peptide 1 (GLP-1). Mol Metab 30:72\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.09.010","journal-title":"Mol Metab"},{"key":"5813_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1001\/jamaophthalmol.2025.2489","volume":"143","author":"GR Natividade","year":"2025","unstructured":"Natividade GR, Spiazzi BF, Baumgarten MW, Bassotto C, Pereira AA, Fraga BL, Scalco BG, Mattes NR, Lavinsky D, Kramer CK, Gerchman F (2025) Ocular adverse events with semaglutide: a systematic review and meta-analysis. JAMA Ophthalmol 143:759\u2013768. https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.2489","journal-title":"JAMA Ophthalmol"},{"key":"5813_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"5813_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12676","author":"A Nguyen","year":"2024","unstructured":"Nguyen A, Smith E, Hashemy H, Agarwal SM, Hahn MK, Paterson AD, Dash S (2024) Glucagon-like-peptide 1 receptor agonism and attempted suicide: a Mendelian randomisation study to assess a potential causal association. Clin Obes. https:\/\/doi.org\/10.1111\/cob.12676","journal-title":"Clin Obes"},{"key":"5813_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/vision7040072","volume":"7","author":"ML Salvetat","year":"2023","unstructured":"Salvetat ML, Pellegrini F, Spadea L, Salati C, Zeppieri M (2023) Non-arteritic anterior ischemic optic neuropathy (NA-AION): a comprehensive overview. Vision (Basel) 7:72. https:\/\/doi.org\/10.3390\/vision7040072","journal-title":"Vision (Basel)"},{"key":"5813_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE, Rosenstock J, Gerstein HC (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9:653\u2013662. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5813_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.23385","author":"G Schoretsanitis","year":"2024","unstructured":"Schoretsanitis G, Weiler S, Barbui C, Raschi E, Gastaldon C (2024) Disproportionality analysis from World Health Organization data on semaglutide, liraglutide, and suicidality. JAMA Netw Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.23385","journal-title":"JAMA Netw Open"},{"key":"5813_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/dom.12251","volume":"16","author":"J Seufert","year":"2014","unstructured":"Seufert J, Gallwitz B (2014) The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab 16:673\u2013688. https:\/\/doi.org\/10.1111\/dom.12251","journal-title":"Diabetes Obes Metab"},{"key":"5813_CR29","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2174\/011570159X349579241231080602","volume":"23","author":"A Sharafshah","year":"2025","unstructured":"Sharafshah A, Lewandrowski KU, Gold MS, Fuehrlein B, Ashford JW, Thanos PK, Wang GJ, Hanna C, Cadet JL, Gardner EL, Khalsa JH, Braverman ER, Baron D, Elman I, Dennen CA, Bowirrat A, Pinhasov A, Modestino EJ, Carney PR, Cortese R, Fiorelli RKA, Schmidt S, Pollack AR, Badgaiyan RD, Blum K (2025) In silico pharmacogenomic assessment of glucagon-like peptide-1 (GLP1) agonists and the Genetic Addiction Risk Score (GARS) related pathways: implications for suicidal ideation and substance use disorder. Curr Neuropharmacol 23:974\u2013995. https:\/\/doi.org\/10.2174\/011570159X349579241231080602","journal-title":"Curr Neuropharmacol"},{"key":"5813_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102427","volume":"16","author":"R Shetty","year":"2022","unstructured":"Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, Acharya LD (2022) Adverse drug reactions of GLP-1 agonists: a systematic review of case reports. Diabetes Metab Syndr 16:102427. https:\/\/doi.org\/10.1016\/j.dsx.2022.102427","journal-title":"Diabetes Metab Syndr"},{"key":"5813_CR31","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1001\/jamainternmed.2024.4369","volume":"184","author":"P Ueda","year":"2024","unstructured":"Ueda P, S\u00f6derling J, Wintzell V, Svanstr\u00f6m H, Pazzagli L, Eliasson B, Melbye M, Hviid A, Pasternak B (2024) GLP-1 receptor agonist use and risk of suicide death. JAMA Intern Med 184:1301\u20131312. https:\/\/doi.org\/10.1001\/jamainternmed.2024.4369","journal-title":"JAMA Intern Med"},{"key":"5813_CR32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ (2023) Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 20:463\u2013474. https:\/\/doi.org\/10.1038\/s41569-023-00849-3","journal-title":"Nat Rev Cardiol"},{"key":"5813_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40261-021-01110-w","volume":"42","author":"F Wang","year":"2022","unstructured":"Wang F, Mao Y, Wang H, Liu Y, Huang P (2022) Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Clin Drug Investig 42:17\u201328. https:\/\/doi.org\/10.1007\/s40261-021-01110-w","journal-title":"Clin Drug Investig"},{"key":"5813_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.119670","volume":"389","author":"M Wang","year":"2025","unstructured":"Wang M, Yang Z, Yan M, Liu S, Xiao S (2025) Depression and suicide\/self-injury signals for weight loss medications: a disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database. J Affect Disord 389:119670. https:\/\/doi.org\/10.1016\/j.jad.2025.119670","journal-title":"J Affect Disord"},{"key":"5813_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","volume":"22","author":"J Zhou","year":"2024","unstructured":"Zhou J, Zheng Y, Xu B, Long S, Zhu LE, Liu Y, Li C, Zhang Y, Liu M, Wu X (2024) Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database. BMC Med 22:65. https:\/\/doi.org\/10.1186\/s12916-024-03274-6","journal-title":"BMC Med"},{"key":"5813_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12020-024-04112-8","volume":"88","author":"J Zhou","year":"2025","unstructured":"Zhou J, Huang W, Xie Y, Shen H, Liu M, Wu X (2025) Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database. Endocr Res 88:80\u201390. https:\/\/doi.org\/10.1007\/s12020-024-04112-8","journal-title":"Endocr Res"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05813-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05813-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05813-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T01:00:27Z","timestamp":1787360427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05813-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":36,"alternative-id":["5813"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05813-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}